The Hourly View for PFE
Last Updated September 10, 2020, 15:15 GMT
At the time of this writing, PFE’s price is down $-0.1 (-0.29%) from the hour prior. This move is a reversal from the hour prior, which saw price move down. Regarding the trend, note that the strongest trend exists on the 50 hour timeframe. The moving averages on the hourly timeframe suggest a bullishness in price, as the 20, 50 and 100 are all in a bullish alignment — meaning the shorter durations are above the longer duration averages, implying a sound upward trend.
Pfizer Inc Daily Price Recap
The end of a 3 day negative run has come for Pfizer Inc, which finished yesterday up 0.7% ($0.25). The change in price came along side change in volume that was up 1.79% from previous day, but down 17.19% from the Wednesday of last week. Let’s take a look at the daily price chart of Pfizer Inc.
Pfizer Inc Technical Analysis
Notably, the current price of Pfizer Inc is sitting close to its 100 and 200 day moving averages; moving average crosses often indicate a change in momentum, so this may be worth keeping an eye on. Trend traders will want to observe that the strongest trend appears on the 14 day horizon; over that time period, price has been moving down. For additional context, note that price has gone down 7 out of the past 10 days. Also, candlestick traders! Note we see pin bar pattern appearing here as well.
Overheard Around the Web
Here’s what one trader on StockTwits recently had to say in regards to PFE:
$MRNA $PFE $BNTX
Scientists question Russian vaccine trial data
A group of scientists have questioned the reliability of data published by Russian epidemiologists on early clinical trials of its “Sputnik V” coronavirus vaccine.
In an open letter to the editor of The Lancet medical journal, in which Russia’s Gamaleya Research Institute of Epidemiology and Microbiology published early-stage trial results of its coronavirus vaccine last week, a group of scientists said the data showed some “unlikely patterns.”
One of the signatories of the letter, Professor Enrico Bucci from Temple University, told CNBC that further data was needed.
“At this point, I need an explanation and we need clarification, the list of signatories need and ask for clarification … The point here (is that there’s) missing data, and strange data patterns. We cannot reach a conclusion on this vaccine without having full access to the data,” he said. —Holly Ellyatt